Can Tighter Control Improve the Course of Crohn’s Disease?
BACKGROUND AND PURPOSE:
The goal of treatment in Crohn’s disease is to achieve clinical and endoscopic remission
Biomarkers of intestinal inflammation, such as fecal calprotectin and C-reactive protein (CRP), may be beneficial in the monitoring of patients with Crohn’s disease
Colombel et al. (Lancet, 2017) assessed the endoscopic and clinical outcomes in patients in which these biomarkers were used to direct treatment decisions vs those treated with clinical parameters alone
Open-label, randomized, controlled phase 3 study (RCT)
Patients between ages 18-75 years with active (moderate or severe) endoscopic Crohn’s disease, a Crohn’s Disease Activity Index (CDAI) of 150–450 depending on dose of prednisone at baseline, and no previous use of immunomodulators or biologics
Patients were randomized into the following groups
Tight control based on biomarkers and clinical symptoms
Clinical management only
Groups were stratified after 8 weeks of prednisone induction therapy, or earlier if they had active disease based on
Smoking status (yes or no)
Weight (<70 kg or ≥70 kg)
Disease duration (≤2 years or >2 years)
Both treatment plans were escalated base on meeting treatment failure criteria
The primary outcome was mucosal healing (CDEIS <4) with absence of deep ulcers 48 weeks after randomization
Primary and safety analyses were done in the intention-to-treat population.
244 patients were divided into equal groups
A significantly higher proportion of patients in the tight control group achieved the primary outcomes at week 48 (46%) than in the clinical management group (30%)
The risk difference between groups was 16.1% (95% CI 3.9–28.3; p=0·010)
86% of tight control group and 82% in the clinical management group reported treatment-emergent adverse events; no treatment-related deaths occurred
Timely escalation of therapy combining clinical judgement with biomarkers in patients with early Crohn’s disease results in better clinical and endoscopic outcomes than symptom-driven decisions alone
Future studies should assess the effects of such a strategy on long-term outcomes such as bowel damage, surgeries, hospital admissions, and disability
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan